Arkansas Urology today announced Dr. Timothy Goodson’s practice at Arkansas Urology has been selected a UroLift® System Center of Excellence by NeoTract, a wholly owned subsidiary of Teleflex Incorporated. This is the first distinction of its kind in the state of Arkansas. The UroLift® System is a treatment for benign prostatic hyperplasia (BPH, or enlarged prostate), a condition that affects roughly 50% of men over the age of 50 and 90% of men over 80. It is non-surgical, makes no physical change to the gland through cutting or lasers, and offers immediate relief of the most common symptoms. “UroLift is held in great regard in my practice because it’s so comfortable for patients and so consistent in its results. I can do it in an exam room in under an hour. It doesn’t preclude other treatments down the line, and it’s caused no unintended side effects in any of my patients,” Goodson said. “We’re thrilled to offer this treatment option, and I’m proud to be associated with it at this level.”
Dr. Goodson joined Arkansas Urology in 2002. A graduate of Ouachita Baptist University and the University of Arkansas for Medical Sciences, he is a member of the American Urological Association and president of the Arkansas Urological Society. He serves on the Medical Advisory Board of the Arkansas Prostate Cancer Foundation and has been instrumental in bringing new prostate cancer treatments to the region. “We’re happy to provide this state-of-the-art, non-surgical treatment here. Tens of thousands of Arkansans are affected by BPH and suffer symptoms, everything from urinary discomfort to interrupted sleep, even depression and loss of productivity,” said E. Scot Davis, CEO of Arkansas Urology. “This is such a quick and safe procedure; it’s a relief in more ways than one.” For information about the procedure, including a BPH quiz and UroLift video, visit ArkansasUrology.com/urolift-system, or call (501) 219-8900.
About the UroLift® System The FDA-cleared UroLift System is a proven, minimally invasive technology or treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without
compromising sexual function. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.
